Effects of the bone morphogenetic protein binding protein spp24 (secreted phosphoprotein 24 kD) on the growth of human lung cancer cells

Journal of Orthopaedic Research

Volumn 29, Issue 11, 2011, Pages 1712-1718

  Lee, Kwang Bok ^a,b   Murray, Samuel S ^c,d   Duarte, M Eugenia L ^e   Spitz, Juliana F ^e   Johnson, Jared S ^a   Song, Kyung Jin ^b   Brochmann, Elsa J ^c,d   Taghavi, Cyrus E ^a   Keorochana, Gun ^a   Liao, Jen Chung ^a   Wang, Jeffrey C ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Chonbuk National University Medical School   (South Korea)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

A549 cell line; bone morphogenetic proteins; bone tumors; lung cancer; metastases; spp24

Indexed keywords

PHOSPHOPROTEIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT PROTEIN; RECOMBINANT SECRETED PHOSPHOPROTEIN 24; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BONE RADIOGRAPHY; BONE TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG PROTEIN BINDING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG CANCER; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TIBIA; TUMOR GROWTH;

ANIMALS; AUTOCRINE COMMUNICATION; BONE MORPHOGENETIC PROTEIN 2; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTATINS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, SCID; PHOSPHOPROTEINS; RECOMBINANT PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 80053202817     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21383     Document Type: Article

References (30)

1. Gazzerro E, Canalis E,. 2006. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 7: 51-65. (Pubitemid 46044349)
2. Lyons KE, Pelton RW, Hogan BLM,. 1990. Organogenesis and pattern formation in the mouse: RNA distribution pattern suggests a role for bone morphogeneic protein-2A (BMP-2a). Development 109: 833-844.
3. Canalis E, Economides AN, Gazzarro E,. 2003. Bone morphogenetic protein, their antagonists, and the skeleton. Endo Rev 24: 218-235. (Pubitemid 36515285)
4. McKay WF, Peckham SM, Badura JM,. 2007. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft). Int Orthop 31: 729-734. (Pubitemid 350160311)
5. Hing KA,. 2004. Bone repair in the twenty-first century: Biology, chemistry or engineering? Philosophical Trans Royal Soc London A 362 (1825): 2821-2850. (Pubitemid 40008008)
6. Sandhu H, Khan SN,. 2003. Recombinant human bone morphogenetic protein-2: Use in spinal fusion applications. J Bone Joint Surg 85-A (Suppl. 3): 89-95. (Pubitemid 36951120)
7. Behnam K, Phillips ML, Silva JDP, et al. 2005. BMP binding peptide: A BMP-2 enhancing factor deduced from the sequence of native bovine bone morphogenetic protein/non-collagenous protein. J Orthop Res 23: 175-180. (Pubitemid 40045092)
8. Sintuu C, Murray SS, Behnam K, et al. 2008. Full-length bovine spp24 [spp24 (24-203] inhibits BMP-2 induced bone formation. J Orthop Res 26: 753-758.
9. Brochmann EJ, Simon RJ, Jawien J, et al. 2010. Carboxy terminus of secreted phosphoprotein-24 kDa (spp24) is essential for full inhibition of BMP-2 activity. J Orthop Res 28: 1200-1207.
10. Brochmann EJ, Behnam K, Murray SS,. 2009. Bone morphogenetic protein-2 activity is regulated by secreted phosphoprotein-24 kD, an extracellular pseudoreceptor, the gene for which maps to a region of the human genome important for bone quality. Metab Clin Exp 58: 644-650.
11. Langenfeld EM, Calvano SE, Abou-Nukta F, et al. 2003. The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 24: 1445-1454. (Pubitemid 37160834)
12. Feeley BT, Liu NQ, Conduah AH, et al. 2006. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc Administration. J Bone Min Res 21: 1571-1580. (Pubitemid 44484602)
13. Murray EJB, Murray SS, Simon R, et al. 2007. Recombinant expression, isolation, and proteolysis of extracellular matrix secreted phophoprotein-24 kDa. Connect Tiss Res 48: 1-8.
14. Lee Y-P, Schwarz EM, Davies M, et al. 2002. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 62: 5564-5570.
15. Lee Y, Schwarz E, Davies M, et al. 2003. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 21: 62-72. (Pubitemid 36157621)
16. Langenfeld EM, Bojnowski J, Perone J, et al. 2005. Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg 80: 1028-1032. (Pubitemid 41196808)
17. Langenfeld EM, Kong Y, Langenfeld J,. 2006. Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. Oncogene 25: 685-692. (Pubitemid 43214695)
18. Masuda H, Fukabori Y, Nakano K, et al. 2003. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 54: 268-274. (Pubitemid 36228163)
19. Feeley BT, Krenek L, Liu N, et al. 2006. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 38: 154-166. (Pubitemid 43165781)
20. Feeley BT, Gamradt SC, Hsu WK, et al. 2005. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 20: 2189-2199. (Pubitemid 41698782)
21. Ghosh-Choudhury N, Woodruff K, Qi W, et al. 2000. Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclin-dependent kinase-mediated retinoblastoma protein phosphorylation. Biochem Biophys Res Comm 272: 705-711. (Pubitemid 30420703)
22. Pouliot F, Labrie C,. 2000. Role of Smad1 and Smad4 proteins in the induction of p21WAF1,Cip1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells. J Endocrinol 172: 187-198. (Pubitemid 34082957)
23. Kim IY, Lee DH, Lee DK, et al. 2003. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clin Cancer Res 9 (16 Pt 1): 6046-6051. (Pubitemid 38018092)
24. Soda H, Raymond E, Sharma S, et al. 1998. Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units. Anti-Cancer Drugs 9: 327-331. (Pubitemid 28241822)
25. Orui H, Imaizumi S, Ogino T, et al. 2000. Effects of bone morphogenetic protein-2 on human tumor cell growth and differentiation: A preliminary report. J Orthop Sci 5: 600-604. (Pubitemid 32016269)
26. Koenenman KS, Yeung F, Chung LW,. 1999. Osteomimetic properties of prostate cancer cells. A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39: 246-261. (Pubitemid 29244499)
27. Harris SE, Harris MA, Mahy P, et al. 1994. Expression of BMP mRNAs by normal rat and human prostate and prostate cancer cells. Prostate 24: 204-211. (Pubitemid 24122069)
28. Sen A, Walker MA, Einarson B,. 1987. Purification and partial characterization of a novel osteogenic protein. In:, Sen A, Thornhill T, editors. Development and diseases of cartilage and bone matrix. New York: Alan R. Liss, Inc; p 201-220.
29. Urist MR, Huo YK, Brownell AG, et al. 1984. Purification of bovine bone morphogenetic protein by hydroxyapatite chromatography. Proc Natl Acad Sci USA 81: 371-375. (Pubitemid 14185731)
30. Clines GA, Guise TA,. 2005. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocrin-Rel Cancer 12: 549-583. (Pubitemid 41482993)